Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Don’t stress about CRF: assessing the translational failures of CRF1antagonists
Samantha R. Spierling, Eric P. Zorrilla
Psychopharmacology (2017) Vol. 234, Iss. 9-10, pp. 1467-1481
Open Access | Times Cited: 156

Showing 1-25 of 156 citing articles:

Neurobiology of Opioid Addiction: Opponent Process, Hyperkatifeia, and Negative Reinforcement
George F. Koob
Biological Psychiatry (2019) Vol. 87, Iss. 1, pp. 44-53
Closed Access | Times Cited: 399
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Amir Garakani, James W. Murrough, Rafael C. Freire, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 313
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
George F. Koob
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 163-201
Open Access | Times Cited: 237
The Corticotropin-Releasing Factor Family: Physiology of the Stress Response
Jan M. Deussing, Alon Chen
Physiological Reviews (2018) Vol. 98, Iss. 4, pp. 2225-2286
Open Access | Times Cited: 221
Is the HPA Axis as Target for Depression Outdated, or Is There a New Hope?
Andreas Menke
Frontiers in Psychiatry (2019) Vol. 10
Open Access | Times Cited: 216
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
Simone B. Sartori, Nicolas Singewald
Pharmacology & Therapeutics (2019) Vol. 204, pp. 107402-107402
Open Access | Times Cited: 206
Visceral Pain
Luke Grundy, Andelain Erickson, Stuart M. Brierley
Annual Review of Physiology (2018) Vol. 81, Iss. 1, pp. 261-284
Closed Access | Times Cited: 202
The human hypothalamus in mood disorders: The HPA axis in the center
Ai‐Min Bao, Dick F. Swaab
IBRO Reports (2018) Vol. 6, pp. 45-53
Open Access | Times Cited: 172
Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry
Andrew H. Miller, Michael Berk, Gilles Bloch, et al.
Brain Behavior and Immunity (2025) Vol. 125, pp. 319-329
Closed Access | Times Cited: 3
Sex differences in stress reactivity in arousal and attention systems
Debra A. Bangasser, Samantha R. Eck, Evelyn Ordoñes Sanchez
Neuropsychopharmacology (2018) Vol. 44, Iss. 1, pp. 129-139
Open Access | Times Cited: 146
Individual differences in the neuropsychopathology of addiction
Olivier George, George F. Koob
Dialogues in Clinical Neuroscience (2017) Vol. 19, Iss. 3, pp. 217-229
Open Access | Times Cited: 109
Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice
Johan Kakko, Hannu Alho, Alex Baldacchino, et al.
Frontiers in Psychiatry (2019) Vol. 10
Open Access | Times Cited: 106
Animals, anxiety, and anxiety disorders: How to measure anxiety in rodents and why
Jaanus Harro
Behavioural Brain Research (2017) Vol. 352, pp. 81-93
Closed Access | Times Cited: 100
ADULT NEUROGENESIS IN HUMANS: A Review of Basic Concepts, History, Current Research, and Clinical Implications.
Masaru Nakamura, Takahiko Nagamine
PubMed (2019) Vol. 16, Iss. 5-6, pp. 30-37
Closed Access | Times Cited: 100
Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies
Andrew H. Miller, Charles L. Raison
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 68-75
Closed Access | Times Cited: 46
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders
Jeffrey M. Witkin, Arnold S. Lippa, Jodi L. Smith, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 213, pp. 173321-173321
Closed Access | Times Cited: 39
The HPA Axis as Target for Depression
Andreas Menke
Current Neuropharmacology (2023) Vol. 22, Iss. 5, pp. 904-915
Open Access | Times Cited: 26
Medications for alcohol use disorders: An overview
Mohammed Akbar, Mark Egli, Young‐Eun Cho, et al.
Pharmacology & Therapeutics (2017) Vol. 185, pp. 64-85
Open Access | Times Cited: 86
Sex differences in the hypothalamic–pituitary–adrenal axis: An obstacle to antidepressant drug development?
Nikolaos Kokras, Georgia E. Hodes, Debra A. Bangasser, et al.
British Journal of Pharmacology (2019) Vol. 176, Iss. 21, pp. 4090-4106
Open Access | Times Cited: 74
The Gut Microbiome and Mental Health: What Should We Tell Our Patients?: Le microbiote Intestinal et la Santé Mentale : que Devrions-Nous dire à nos Patients?
Mary I. Butler, Sabrina Mörkl, Kiran V. Sandhu, et al.
The Canadian Journal of Psychiatry (2019) Vol. 64, Iss. 11, pp. 747-760
Open Access | Times Cited: 74
Central Amygdala Projections to Lateral Hypothalamus Mediate Avoidance Behavior in Rats
Marcus M. Weera, Rosetta S. Shackett, Hannah M. Kramer, et al.
Journal of Neuroscience (2020) Vol. 41, Iss. 1, pp. 61-72
Open Access | Times Cited: 67
Is AD a Stress-Related Disorder? Focus on the HPA Axis and Its Promising Therapeutic Targets
Geoffrey Canet, Célia Hernandez, Charleine Zussy, et al.
Frontiers in Aging Neuroscience (2019) Vol. 11
Open Access | Times Cited: 66
Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience
Michael C. Flux, Christopher A. Lowry
Neurobiology of Disease (2019) Vol. 135, pp. 104578-104578
Open Access | Times Cited: 57
Neuropeptide System Regulation of Prefrontal Cortex Circuitry: Implications for Neuropsychiatric Disorders
Sanne M. Casello, Rodolfo J. Flores, Héctor E. Yarur, et al.
Frontiers in Neural Circuits (2022) Vol. 16
Open Access | Times Cited: 35
Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions
Harry Fagan, David S. Baldwin
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 6, pp. 535-548
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top